1.59
Metavia Inc stock is traded at $1.59, with a volume of 54,113.
It is down -1.24% in the last 24 hours and down -8.09% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
See More
Previous Close:
$1.61
Open:
$1.605
24h Volume:
54,113
Relative Volume:
0.22
Market Cap:
$5.27M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
-8.09%
6M Performance:
-79.05%
1Y Performance:
-90.49%
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MTVA
Metavia Inc
|
1.59 | 5.34M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - PR Newswire
Buyout Rumor: Will MetaVia Inc outperform its industry peersMarket Sentiment Summary & Target Return Focused Picks - baoquankhu1.vn
Growth Value: How does FCCO compare to its peersJuly 2025 Review & Verified Trade Idea Suggestions - baoquankhu1.vn
MetaVia: DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year - TradingView
MetaVia: Promising early results for obesity and MASH drugs set up major 2024 data and partnership catalysts - TradingView
Dow Update: Should I invest in MetaVia Inc before earningsJuly 2025 Closing Moves & Accurate Entry/Exit Alerts - baoquankhu1.vn
MTVA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investment Recap: Is MetaVia Inc currently under institutional pressureTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Hedge Fund Bets: Why is CCNE stock going downJuly 2025 Big Picture & Community Verified Trade Signals - baoquankhu1.vn
Chart Watch: What are CIOPRAs recent SEC filings showingJuly 2025 Market Mood & Community Trade Idea Sharing Platform - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) vs. MetaVia (NASDAQ:MTVA) Head-To-Head Survey - Defense World
Aug Ideas: Should I invest in MetaVia Inc before earningsTrade Volume Summary & High Conviction Investment Ideas - baoquankhu1.vn
Trade Recap: Is now the right time to enter MetaVia IncJuly 2025 Setups & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference - PR Newswire
Can MetaVia Inc. stock outperform in a bear marketTreasury Yields & Proven Capital Preservation Methods - mfd.ru
What is the target price for MetaVia Inc. stockEarnings Summary Report & Risk Controlled Swing Alerts - mfd.ru
How MetaVia Inc. stock performs in stagflationTrade Risk Report & Fast Entry and Exit Trade Plans - mfd.ru
MetaVia secures patent protection for obesity treatment through 2041 - Investing.com India
Metavia builds comprehensive global patent protection for DA-1726, securing exclusive rights to novel obesity and metabolic therapy - marketscreener.com
Can MetaVia Inc. continue delivering strong returnsMarket Movers & Entry Point Confirmation Signals - mfd.ru
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 - PR Newswire
Will MetaVia Inc. outperform its industry peers2025 Historical Comparison & Fast Entry and Exit Trade Plans - mfd.ru
Will MetaVia Inc. stock go up in YEAROil Prices & Real-Time Volume Surge Alerts - mfd.ru
Earnings Recap: What analysts say about MetaVia Inc. stockWeekly Investment Report & Fast Gaining Stock Strategy Reports - mfd.ru
MetaVia (MTVA) Stock Price, News & Analysis - MarketBeat
Aug Drivers: Does MetaVia Inc outperform in volatile markets2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn
Technical Analysis: Is now the right time to enter MetaVia IncJuly 2025 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
AI modeling confirms therapeutic targets for MetaVia’s vanoglipel By Investing.com - Investing.com Australia
Metavia Inc announces positive AI-modeling results from ongoing SyntekaBio collaboration, confirming key therapeutic targets for Vanoglipel - marketscreener.com
AI modeling confirms therapeutic targets for MetaVia’s vanoglipel - Investing.com
Metavia IncAnnounces Positive Ai-Modeling Results From Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets For Vanoglipel - TradingView
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel - ChartMill
Bear Alert: Is REVBW a potential multi baggerWall Street Watch & Momentum Based Trading Signals - baoquankhu1.vn
Breakout Watch: Is MetaVia Inc in a consolidation phase2025 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug EndMonth: How correlated is RNAC to the S P500July 2025 Weekly Recap & Daily Stock Trend Reports - baoquankhu1.vn
MetaVia Updates 2025 Executive Discretionary Bonus Disclosure - TipRanks
Gainers Report: What is the next catalyst for MetaVia IncWatch List & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Aug Selloffs: Will MetaVia Inc benefit from seasonalityWeekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn
Market Outlook: What is the PEG ratio of MetaVia Inc2025 Short Interest & Community Verified Watchlist Alerts - baoquankhu1.vn
Aug PreEarnings: What are analysts’ price targets for SLND.WS2025 Trading Volume Trends & Fast Gain Swing Alerts - baoquankhu1.vn
Aug Decliners: Can MetaVia Inc continue delivering strong returns2025 Risk Factors & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
MTVA Stock Price, Forecast & Analysis | METAVIA INC (NASDAQ:MTVA) - Chartmill
MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726… - Yahoo Finance
Trade Report: Can MetaVia Inc stock outperform in a bear marketJuly 2025 Rallies & Weekly Market Pulse Alerts - baoquankhu1.vn
What Does the Market Think About MetaVia Inc? - Sahm
MetaVia (NASDAQ:MTVA) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Aug Reactions: Is SWKH impacted by rising rates2025 Support & Resistance & Momentum Based Trading Ideas - baoquankhu1.vn
Aug Update: Does MetaVia Inc have strong fundamentalsPortfolio Gains Report & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
MetaVia closes $9.3 million public offering with full exercise of option - Investing.com Nigeria
MetaVia prices $8.1M underwritten public offering - MSN
MetaVia Completes Public Offering to Advance Obesity Drug - TipRanks
Metavia Inc Stock (MTVA) Financials Data
There is no financial data for Metavia Inc (MTVA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Metavia Inc Stock (MTVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DONG-A ST CO., LTD | 10% Owner |
May 08 '25 |
Buy |
0.71 |
4,647,887 |
3,300,000 |
9,995,679 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):